adidas AG

  • WKN: A1EWWW
  • ISIN: DE000A1EWWW0
  • Land: Deutschland

Nachricht vom 11.04.2019 | 15:59

DGAP-DD: adidas AG english


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

11.04.2019 / 15:59
The issuer is solely responsible for the content of this announcement.


1. Details of the person discharging managerial responsibilities / person closely associated

a) Name
Title:
First name: Hans
Last name(s): Ruprecht

2. Reason for the notification

a) Position / status
Position: Member of the administrative or supervisory body

b) Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name
adidas AG

b) LEI
549300JSX0Z4CW0V5023 

4. Details of the transaction(s)

a) Description of the financial instrument, type of instrument, identification code
Type: Share
ISIN: DE000A1EWWW0

b) Nature of the transaction
The notification on hand is regarding the receipt of 3.305624 adidas AG shares free of charge as part of the employee share purchase program of adidas AG (matching shares).
Transaction linked to the exercise of share option programmes

c) Price(s) and volume(s)
Price(s) Volume(s)
not numberable not numberable

d) Aggregated information
Price Aggregated volume
not numberable not numberable

e) Date of the transaction
2019-04-09; UTC+2

f) Place of the transaction
Name: Frankfurter Wertpapierbörse (FWB) - Xetra
MIC: XETR



11.04.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

PSI Software AG

Original-Research: PSI AG (von First Berlin Equity Research GmbH): Hinzufügen

06. Dezember 2021